Preclinical and clinical studies on CAR-NK cell therapy: latest update from 2025 ASH Annual Meeting
{{output}}
Chimeric antigen receptor-engineered natural killer (CAR-NK) cells are emerging as an off-the-shelf immunotherapy for hematologic malignancies, supported by early clinical data and a favorable safety profile. Compared with CAR-T therapy, CAR-NK cells offer the... ...
